Blog
RSS FeedPosted by Michael Wonder on 31 Aug 2025
FDA approval of Leqembi subcutaneous formulation charts path to combination therapies for Alzheimer's disease
29 August 2025 - Subcutaneous delivery increases accessibility and introduces potential for at home administration, following model of diabetes and ...
Posted by Michael Wonder on 02 Jul 2024
Multiple myeloma treatments available to more people
2 July 2024 - PHARMAC is making more treatment options available for people with multiple myeloma and other blood disorders. ...
Posted by Michael Wonder on 02 Jul 2024
FDA approves treatment for adults with Alzheimer’s disease
2 July 2024 - The US FDA has approved Kisunla (donanemab-azbt) injection for the treatment of Alzheimer’s disease. ...
Posted by Michael Wonder on 02 Jul 2024
ICER publishes evidence report on treatment for anaemia in myelodysplastic syndrome
2 July 2024 - There are significant uncertainties regarding long term efficacy and safety of imetelstat; treatment would achieve common ...
Posted by Michael Wonder on 02 Jul 2024
FDA breakthrough therapy designation reduced late-stage drug development time
1 July 2024 - The FDA’s breakthrough therapy designation program was created to increase patient access to safe and effective therapies ...
Posted by Michael Wonder on 02 Jul 2024
Altos Biologics files for approval of aflibercept biosimilar
1 July 2024 - Alteogen announced on 1 July that its subsidiary, Altos Biologics submitted a marketing authorisation application to ...
Posted by Michael Wonder on 02 Jul 2024
Standardisation of practice on publication of indications in Swiss Public Assessment Report
1 July 2024 - In order to standardise practice, Swissmedic will in future publish both the proposed and approved indications in ...
Posted by Michael Wonder on 02 Jul 2024
Longboard Pharmaceuticals receives breakthrough therapy designation for bexicaserin
1 July 2024 - Longboard Pharmaceuticals today announced that the FDA has granted breakthrough therapy designation for its investigational drug ...
Posted by Michael Wonder on 02 Jul 2024
SpringWorks Therapeutics completes submission of new drug application to the FDA for mirdametinib for the treatment of children and adults with NF1-PN
1 July 2024 - SpringWorks Therapeutics announced today that the Company has completed the submission of a new drug application to ...
Posted by Michael Wonder on 02 Jul 2024
Idorsia’s Jeraygo (aprocitentan) approved in Europe as first and only ERA for the treatment of resistant hypertension
1 July 2024 - Jeraygo is a new oral antihypertensive therapy – the first in almost 40 years – that is ...
Posted by Michael Wonder on 02 Jul 2024
Pierre Fabre Laboratories announce granting of European marketing authorisation for Obgemsa (vibegron) in overactive bladder
28 June 2024 - The European Commission has authorised the marketing of Obgemsa (vibegron) by Pierre Fabre Laboratories for the symptomatic ...
Posted by Michael Wonder on 02 Jul 2024
Valneva receives marketing authorisation in Europe for the world’s first chikungunya vaccine Ixchiq
1 July 2024 - 2024 – Valneva today announced that the European Commission has granted marketing authorisation in Europe for Valneva’s ...
Posted by Michael Wonder on 02 Jul 2024
New and expanded PBS listings for breast cancer, leukaemia and lupus treatments
2 July 2024 - Australians with early breast cancer, leukaemia, and types of lupus, and insomnia, will now have access to ...
Posted by Michael Wonder on 02 Jul 2024
Syncromune granted FDA fast track designation for SYNC-T SV-102 for the treatment of metastatic castrate-resistant prostate cancer
1 July 2024 - Syncromune today announced that the US FDA has granted fast track designation for SYNC-T SV-102 therapy, its ...
Posted by Michael Wonder on 01 Jul 2024
Antengene announces Xpovio (selinexor) National Health Insurance Service approval for reimbursement in South Korea
26 June 2024 - The approval of Xpovio by the NHIS in South Korea is the fourth national reimbursement in the ...
Posted by Michael Wonder on 01 Jul 2024
Neurocrine Biosciences announces US FDA accepts new drug applications and grants priority review for crinecerfont for paediatric and adult patients with CAH
1 July 2024 - PDUFA target action dates in late December 2024. ...